P Garnero

Summary

Affiliation: Synarc Inc
Country: France

Publications

  1. ncbi Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring
    Patrick Garnero
    INSERM Unit 664, Laennec School of Medicine, Lyon, France
    Mol Diagn Ther 12:157-70. 2008
  2. ncbi Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein
    Stephanie O Keeling
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Rheumatol 34:623-33. 2007
  3. ncbi Bone markers in osteoporosis
    Patrick Garnero
    Synarc, 16 rue Montbrillant, 69003 Lyon, France
    Curr Osteoporos Rep 7:84-90. 2009
  4. ncbi Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of th
    Patrick Garnero
    INSERM Unit 664, Lyon, France
    Arthritis Rheum 62:33-43. 2010
  5. pmc Increased Dickkopf-1 expression in breast cancer bone metastases
    N Voorzanger-Rousselot
    Molecular Markers, Synarc, Lyon F 69416, France
    Br J Cancer 97:964-70. 2007
  6. pmc Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation
    N Voorzanger-Rousselot
    Molecular Markers, Synarc, 16 rue Montbrillant, Le Buroparc T4, 69416 Lyon Cedex 03, France
    Br J Cancer 95:506-14. 2006
  7. pmc The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover
    Anne Christine Bay-Jensen
    Department of Clinical Cell Biology, IRS CSFU, University of Southern Denmark, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark
    Arthritis Res Ther 11:R9. 2009
  8. pmc Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
    Tim D Spector
    Twin Research and Genetic Epidemiology Unit, St Thomas Hospital, London, UK
    Arthritis Res Ther 7:R625-33. 2005
  9. pmc Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers
    Erik B Dam
    Nordic Bioscience, Herlev Hovedgade 207, Herlev, Denmark
    Arthritis Res Ther 11:R115. 2009
  10. ncbi Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis
    Patrick Garnero
    INSERM Unit 664, Synarc Lyon, 16 rue Montbrillant, Lyon, France
    Clin Chem 54:188-96. 2008

Collaborators

Detail Information

Publications106 found, 100 shown here

  1. ncbi Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring
    Patrick Garnero
    INSERM Unit 664, Laennec School of Medicine, Lyon, France
    Mol Diagn Ther 12:157-70. 2008
    ..Thus, repeated measurements of bone markers during therapy may help improve the management of osteoporosis in patients...
  2. ncbi Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein
    Stephanie O Keeling
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Rheumatol 34:623-33. 2007
    ..2) To assess the strength of recommendation for inclusion of individual criteria in the draft set...
  3. ncbi Bone markers in osteoporosis
    Patrick Garnero
    Synarc, 16 rue Montbrillant, 69003 Lyon, France
    Curr Osteoporos Rep 7:84-90. 2009
    ..This brief review discusses these novel technological developments and the recent clinical data on the use of established and new markers in postmenopausal osteoporosis...
  4. ncbi Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of th
    Patrick Garnero
    INSERM Unit 664, Lyon, France
    Arthritis Rheum 62:33-43. 2010
    ....
  5. pmc Increased Dickkopf-1 expression in breast cancer bone metastases
    N Voorzanger-Rousselot
    Molecular Markers, Synarc, Lyon F 69416, France
    Br J Cancer 97:964-70. 2007
    ..Measurements of circulating Dkk-1 levels may be useful for the clinical investigation of patients with breast cancer and bone metastases...
  6. pmc Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation
    N Voorzanger-Rousselot
    Molecular Markers, Synarc, 16 rue Montbrillant, Le Buroparc T4, 69416 Lyon Cedex 03, France
    Br J Cancer 95:506-14. 2006
    ..Markers of bone resorption have the highest independent diagnostic value for detecting and potentially predicting BM in breast carcinoma patients...
  7. pmc The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover
    Anne Christine Bay-Jensen
    Department of Clinical Cell Biology, IRS CSFU, University of Southern Denmark, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark
    Arthritis Res Ther 11:R9. 2009
    ..Here we investigate whether this response to oestrogen is also true for other type II collagen turnover markers known to be affected in osteoarthritis, and whether it relates to its presence in specific areas of cartilage tissue...
  8. pmc Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
    Tim D Spector
    Twin Research and Genetic Epidemiology Unit, St Thomas Hospital, London, UK
    Arthritis Res Ther 7:R625-33. 2005
    ..Both doses of risedronate were well tolerated. In this study, clear trends towards improvement were observed in both joint structure and symptoms in patients with primary knee OA treated with risedronate...
  9. pmc Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers
    Erik B Dam
    Nordic Bioscience, Herlev Hovedgade 207, Herlev, Denmark
    Arthritis Res Ther 11:R115. 2009
    ..Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality...
  10. ncbi Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis
    Patrick Garnero
    INSERM Unit 664, Synarc Lyon, 16 rue Montbrillant, Lyon, France
    Clin Chem 54:188-96. 2008
    ..We evaluated the performance of a fully automated assay for serum total N-terminal propeptide of type I collagen (P1NP), a marker of bone formation...
  11. ncbi Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial
    Patrick Garnero
    INSERM Research Unit 403 and Synarc, Lyon, France
    Hum Reprod 17:2748-53. 2002
    ....
  12. ncbi Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study
    P Garnero
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 31:43-50. 2002
    ..Larger long-term studies are necessary to assess adequately the relationships between IL-6 genotype, rate of bone loss, and risk of fracture...
  13. ncbi Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
    P Garnero
    INSERM Research Unit 664, Lyon, France
    Osteoarthritis Cartilage 16:660-6. 2008
    ....
  14. ncbi Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort
    Patrick Garnero
    INSERM Unit 403 and Molecular Markers, Synarc, Lyon, France
    J Rheumatol 32:697-703. 2005
    ..To investigate the associations of molecular markers of joint tissue turnover with clinical and radiological variables in patients with hip osteoarthritis (OA)...
  15. ncbi Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study
    Patrick Garnero
    INSERM Research Unit 403, and Synarc, Lyon, France
    Arthritis Rheum 46:2847-56. 2002
    ....
  16. ncbi An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis
    P Garnero
    INSERM Research Unit 403, Hôpital E Herriot Pavillon F, 69437 Lyon Cedex 03, France
    Bone 32:20-6. 2003
    ..The test was a sensitive indicator of the antiresorptive effects of bisphosphonate and estrogens in postmenopausal women. This new bone resorption marker should be useful for the clinical investigation of patients with osteoporosis...
  17. ncbi The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    J Bone Miner Res 18:859-67. 2003
    ..We conclude that the generation of ICTP and CTX depends on different collagenolytic pathways. This finding may explain why these two markers may discriminate between different bone pathologies...
  18. ncbi Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Rheumatol 35:2313-5. 2008
    ..Dickkopf-1 (Dkk-1) regulates bone remodeling in animal models of inflammatory arthritis, but its role in patients with rheumatoid arthritis (RA) remains unclear...
  19. ncbi Biochemical markers of joint tissue turnover in early rheumatoid arthritis
    P Garnero
    University Hospital Maastricht, Maastricht, The Netherlands
    Clin Exp Rheumatol 21:S54-8. 2003
    ....
  20. pmc Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis
    P Garnero
    INSERM Research Unit 403, Lyon, France
    Ann Rheum Dis 62:939-43. 2003
    ..To compare type II collagen degradation using a new urinary specific marker in patients with rapidly destructive and those with slowly progressive hip OA...
  21. ncbi Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study
    P Garnero
    Synarc 16 rue Montbrillant 69003, Lyon, France
    Bone 40:716-22. 2007
    ..The aim of this study was to investigate the associations between serum 25-hydroxyvitamin D (25-OH D), bone turnover markers, bone mineral density (BMD), radius bone loss and incidence of fracture in postmenopausal women...
  22. ncbi Biochemical markers in osteoarthritis: will they measure up?
    Patrick Garnero
    INSERM and Synarc Molecular Markers, Molecular Marker Division, Lyon, France
    Nat Clin Pract Rheumatol 2:116-7. 2006
  23. ncbi Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study
    Patrick Garnero
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    J Bone Miner Res 18:1789-94. 2003
    ..Seventy percent to 80% of women classified as having high bone turnover at baseline were similarly classified by the same methods 4 years later...
  24. ncbi Biomarkers in osteoarthritis
    Patrick Garnero
    INSERM Research Unit 403, Lyon, France
    Curr Opin Rheumatol 15:641-6. 2003
    ..Biologic markers reflecting quantitative and dynamic changes of joint tissue turnover represent promising adjunct tools...
  25. doi Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    Bone 44:461-6. 2009
    ..Urinary alpha/betaCTX ratio has been proposed to reflect collagen maturation. We investigated changes in bone turnover and Col I isomerization in adult patients with OI and their relationship with Col I gene mutations...
  26. ncbi Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density
    P Garnero
    Institut National de la Santé et de la Recherche Médicale Research Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
    J Clin Endocrinol Metab 90:4829-35. 2005
    ..Vitamin D receptor (VDR) gene polymorphisms explain only a small part of the genetic influence on the level of bone mineral density (BMD), whereas their effect on fracture remains uncertain...
  27. ncbi Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study
    P Garnero
    Synarc, Lyon, France
    Arthritis Rheum 52:2822-9. 2005
    ....
  28. ncbi Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women
    P Garnero
    INSERM U 403, Hopital E Herriot, Lyon, France
    J Clin Endocrinol Metab 84:2390-7. 1999
    ..The delayed decrease in bone formation observed with intranasal E2 compared to oral E2 may be related to different effects on serum IGF-I levels...
  29. ncbi Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women
    P Garnero
    INSERM Research Unit 403 and Synarc, Lyon, France
    J Musculoskelet Neuronal Interact 4:50-63. 2004
    ..Further studies in osteoporosis should explore the changes in these biochemical parameters of bone matrix as they may represent a key component of bone quality...
  30. ncbi Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study
    Patrick Garnero
    INSERM Research Unit 403, Synarc, Lyon, France
    Arthritis Rheum 50:3137-44. 2004
    ....
  31. ncbi Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone
    Patrick Garnero
    INSERM Unit 403, Hopital E Herriot, Pav F, 69437 Lyon Cedex 03, France
    Bone 38:300-9. 2006
    ..We conclude that the extent and nature of collagen cross-linking contribute to the mechanical properties of fetal bovine cortical bone independently of bone mineral density...
  32. ncbi Use of biochemical markers to study and follow patients with osteoarthritis
    Patrick Garnero
    Synarc, Molecular Markers, Le Buroparc Bâtiment T4, 16 rue Montbrillant, 69003 Lyon, France
    Curr Rheumatol Rep 8:37-44. 2006
    ..Because osteoarthritis involves different tissues and complex biologic processes, a combination of different biochemical markers appears to be the most promising diagnostic strategy...
  33. ncbi Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis
    P Garnero
    INSERM Research Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
    Clin Chem 47:694-702. 2001
    ..Our aim was to evaluate the technical and clinical performances of a new, fully automated assay for serum C-terminal cross-linking telopeptide of type I collagen (CTX), a marker of bone resorption...
  34. pmc Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis
    P Garnero
    Molecular Markers, Synarc, Lyon, France
    Ann Rheum Dis 65:1639-44. 2006
    ..Biochemical markers reflecting the degradation of the type II collagen helical (Helix-II) and type II collagen C telopeptides (CTX-II) have been developed...
  35. ncbi The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Pav F, 69003 Lyon, France
    Bone 28:461-4. 2001
    ..Measurement of type II collagen breakdown by a new urinary biochemical marker may be useful for in vivo assessment of the effects of drugs that potentially inhibit cartilage destruction...
  36. pmc Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage
    P Garnero
    INSERM Research Unit 403, Lyon, France
    Ann Rheum Dis 60:619-26. 2001
    ..The clinical performance of these two new markers was compared with that of a panel of other established biochemical markers of connective tissue metabolism...
  37. ncbi Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers
    Patrick Garnero
    INSERM Research Unit 403, Lyon, France
    Curr Opin Rheumatol 16:428-34. 2004
    ..More specific biologic markers reflecting systemic quantitative and dynamic changes of bone turnover represent promising adjunctive tools...
  38. ncbi Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis
    Patrick Garnero
    Synarc and Inserm Research Unit, Lyon, France
    Arthritis Rheum 46:21-30. 2002
    ....
  39. ncbi Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis
    Patrick Garnero
    INSERM Unit 403, E Herriot Hospital and Synarc, Pavillon F, 69437 Lyon Cedex 03, France
    Arthritis Rheum 46:2613-24. 2002
    ....
  40. ncbi Cross-sectional evaluation of bone metabolism in men
    P Szulc
    INSERM Research Unit 403, Lyon, France
    J Bone Miner Res 16:1642-50. 2001
    ..After the age of 60 years, bone resorption markers--but not bone formation markers--increase in some men and are associated with lower BMD, suggesting that this imbalance is responsible for increasing bone loss in elderly men...
  41. ncbi Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products
    P Garnero
    INSERM Unit 403, Department of Immunology, Hopital Edouard Herriot, Lyon, France
    Bone 24:381-5. 1999
    ..Bone formation appears to be reduced both in patients with and without joint destruction, whereas resorption is increased only in patients with joint destruction in relation to disease activity...
  42. ncbi The collagenolytic activity of cathepsin K is unique among mammalian proteinases
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Pav F, 69437 Lyon Cedex 03, France
    J Biol Chem 273:32347-52. 1998
    ..This property of cathepsin K is unique among mammalian proteinases and is reminiscent of bacterial collagenases. It is likely to be responsible for the key role of cathepsin K in bone resorption...
  43. ncbi Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study
    P Chavassieux
    , , Lyon, France
    J Bone Miner Res 16:89-96. 2001
    ..These effects on cortical bone were reflected by changes in biochemical markers. MDL markedly reduces bone turnover and increases BMD suggesting that this new agent may prevent postmenopausal bone loss...
  44. doi Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis
    D Vosse
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands
    Rheumatology (Oxford) 47:1219-22. 2008
    ....
  45. pmc Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis
    E Gineyts
    INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69003 Lyon, France
    Ann Rheum Dis 63:857-61. 2004
    ....
  46. ncbi Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Osteoporos Int 8:563-9. 1998
    ..If DXA is not available, the combination of history of fracture and urinary CTX performs as well as hip BMD to assess hip fracture risk in elderly women...
  47. pmc Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover
    E Gineyts
    INSERM U403, Hopital E Herriot, Pavillon F, Place d Arsonval, 69437 Lyon Cedex 03, France
    Biochem J 345:481-5. 2000
    ....
  48. ncbi Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation
    E Gineyts
    INSERM Research Unit 403, , Lyon and. SYNARC, Lyon, France
    Rheumatology (Oxford) 40:315-23. 2001
    ..CONCLUSION: Glc-Gal-PYD may be useful for the clinical investigation of patients with joint disease...
  49. doi Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis
    P Richardot
    CCBR SYNARC, Lyon, France
    Osteoarthritis Cartilage 17:1362-7. 2009
    ..We investigated the nitration of type III collagen, a major constituent of synovial membrane, in knee OA...
  50. ncbi Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis
    Robert Landewe
    Department of Internal Medicine Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands
    Arthritis Rheum 50:1390-9. 2004
    ....
  51. doi Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study
    P Garnero
    INSERM Research Unit 1033, Lyon, France
    Osteoporos Int 24:489-94. 2013
    ....
  52. ncbi Cross-sectional and longitudinal assessment of pre- and postmenopausal bone loss with a portable forearm X-ray device: the Ofely study
    F Duboeuf
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 26:131-5. 2000
    ....
  53. ncbi Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis
    J C Rousseau
    INSERM Unit 403, Pavillon F, Hopital E Herriot, Lyon, France
    Osteoarthritis Cartilage 12:440-7. 2004
    ..In addition, we investigated circulating forms recognized by antiserum IIA in pools of serum from healthy adults, patients with OA and patients with RA...
  54. ncbi Quantification of immature and mature collagen crosslinks by liquid chromatography-electrospray ionization mass spectrometry in connective tissues
    E Gineyts
    INSERM Research Unit 831 and Université de Lyon, Lyon, France
    J Chromatogr B Analyt Technol Biomed Life Sci 878:1449-54. 2010
    ..This novel technique should be useful to quantify simultaneously DHLNL, HLNL, PYD and DPD in connective tissues and to evaluate the maturation of collagen by determination of the ratio between immature and mature enzymatic crosslinks...
  55. ncbi Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes
    N R Portero-Muzy
    INSERM UMR 1033 et Université de Lyon, Lyon, France
    Bone 51:714-9. 2012
    ..The distinction of bone sites to study the early effects of anti-osteoporotic therapies appears meaningful in order to approach their site-specific anti-fracture efficacy...
  56. doi The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation
    N Charni-Ben Tabassi
    Synarc, Molecular Markers, Lyon, France
    Osteoarthritis Cartilage 16:1183-91. 2008
    ..In this study we analyzed the release of Helix-II and CTX-II from human cartilage collagen by the proteinases reported to play a role in cartilage degradation...
  57. ncbi A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Bone 24:603-9. 1999
    ..Because this model is independent of the study design, it should be broadly applicable...
  58. ncbi The role of collagen in bone strength
    S Viguet-Carrin
    INSERM Research Unit 403 and Claude Bernard University, Lyon, France
    Osteoporos Int 17:319-36. 2006
    ..To illustrate the role of the crosslinking process of collagen in bone strength, clinical disorders associated with bone collagen abnormalities and bone fragility, such as osteogenesis imperfecta and osteoporosis, are described...
  59. ncbi Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions
    M Chabaud
    Departments of Immunology and Rheumatology, , 69437 Lyon Cedex 03, France
    Cytokine 13:113-8. 2001
    ..As rheumatoid synovium is infiltrated by Th(1)cells, local cell interactions result in a pro-inflammatory pattern with defective repair, which can be reversed at least in part, by a Th(2)pattern...
  60. ncbi Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis
    Nadine Charni
    Synarc, Lyon, France
    Arthritis Rheum 52:1081-90. 2005
    ..The aim of this study was to develop a biochemical marker reflecting the degradation of the helical region of type II collagen and to evaluate its clinical performance in patients with osteoarthritis (OA) and rheumatoid arthritis (RA)...
  61. ncbi Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study
    Patrick Garnero
    INSERM Unit 403, Hĵpital E Herriot, Lyon, France
    J Bone Miner Res 17:826-33. 2002
    ..This suggests that alterations of type I collagen isomerization/racemization that can be detected by changes in urinary CTX ratios may be associated with increased skeletal fragility...
  62. ncbi Biochemical markers of bone formation reflect endosteal bone loss in elderly men--MINOS study
    P Szulc
    INSERM 403 Research Unit, Hopital Edouard Herriot, Claude Bernard University, Lyon, France
    Bone 36:13-21. 2005
    ..In contrast, they do not reflect the periosteal bone formation, probably because the periosteal surface is smaller and has a slower remodelling rate than the endosteal surface...
  63. ncbi Monitoring individual response to hormone replacement therapy with bone markers
    P D Delmas
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 26:553-60. 2000
    ..Our data suggest that bone turnover markers can be used to monitor the BMD response to HRT at the individual level. Whether such monitoring could improve long-term compliance to HRT should be tested prospectively...
  64. pmc Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Bone Miner Res 23:1442-8. 2008
    ..The influence of these biochemical changes of type I collagen on bone fracture resistance remains to be studied...
  65. doi Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations
    Jean Charles Rousseau
    INSERM Research Unit 831, Universite de Lyon, Lyon, France
    Bone 46:897-900. 2010
    ..We investigated whether cartilage degradation is altered in adult patients with mild osteogenesis imperfecta (OI) used as a human model of bone type I collagen-related osteoarthritis (OA)...
  66. ncbi Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover
    Patrick Garnero
    INSERM Research Unit 403, Hĵpital E Herriot, Lyon, France
    J Clin Pharmacol 42:290-6. 2002
    ..Synthetic conjugated estrogens significantly decreased bone resorption and bone formation comparable to that previously reported for estrogen treatments proven efficacious in preventing postmenopausal bone loss...
  67. ncbi The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction
    P P Geusens
    University Hospital, Maastricht, The Netherlands
    Arthritis Rheum 54:1772-7. 2006
    ....
  68. ncbi Markers of bone turnover in prostate cancer
    P Garnero
    INSERM Research Unit 403 and Synarc, Lyon, France
    Cancer Treat Rev 27:187-92; discussion 193-6. 2001
    ..Thus, bone markers are likely to become a useful and objective tool to monitor bisphosphonate treatment and individual the therapy scheme...
  69. ncbi Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study
    Elisabeth Sornay-Rendu
    INSERM Research Unit 403, Pavillon F, E Herriot Hospital, 69437 Lyon Cedex 03, France
    Bone 33:159-66. 2003
    ....
  70. ncbi Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses
    N Voorzanger-Rousselot
    Molecular Markers, Synarc, 16 rue Montbrillant, Le Buroparc T4, Lyon Cedex 03, France
    Cancer Treat Rev 33:230-83. 2007
    ..A combination of different biochemical and imaging markers appears to be the most promising strategy to monitor patients with cancer...
  71. doi The multiple facets of periostin in bone metabolism
    B Merle
    INSERM Research Unit 1033, Pavillon F, Hopital E Herriot, Place d Arsonval, 69437, Lyon Cedex 03, France
    Osteoporos Int 23:1199-212. 2012
    ..The aim of this article is to provide an extensive review on the implications of periostin in bone biology and its potential use in benign and metabolic bone diseases...
  72. pmc Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rh
    G Chevrel
    Department of Immunology, Hopital E Herriot, 69437 Lyon Cedex 03, France
    Ann Rheum Dis 61:730-3. 2002
    ..To evaluate the usefulness of combination treatment with cytokine inhibitors...
  73. pmc Markers of bone turnover for the management of patients with bone metastases from prostate cancer
    P Garnero
    INSERM Research Unit 403, , Lyon, France
    Br J Cancer 82:858-64. 2000
    ..These findings suggest that these new resorption markers may be useful for the management of these patients...
  74. ncbi Monitoring cartilage turnover
    Nadine Charni-Ben Tabassi
    Synarc, Le Buroparc Bâtiment T4, 16, rue Montbrillant, 69003 Lyon, France
    Curr Rheumatol Rep 9:16-24. 2007
    ....
  75. ncbi Biological markers in osteoarthritis
    J Ch Rousseau
    INSERM Unit 1033 Pathophysiology, Diagnosis and Treatments of bone diseases, Universite de Lyon, Lyon, France
    Bone 51:265-77. 2012
    ..In this review, we will use the BIPED classification that appeared in 2006 for OA markers to describe the potential usage of a given marker [5]. This article is part of a Special Issue entitled "Osteoarthritis"...
  76. ncbi [Prescription of bone remodeling markers in hospitals]
    J C Souberbielle
    Inserm Unité 403 et Synarc, 16, rue de Montbrillant, Le Buroparc T4, 69003 Lyon, France
    Ann Biol Clin (Paris) 60:571-9. 2002
    ..We propose that in a given hospital, the present article may serve as a basis for a discussion between clinicians and biologists about the development and/or the optimization of the measurements of these markers of bone turnover...
  77. doi Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases
    Nathalie Voorzanger-Rousselot
    Biochemical Markers, Synarc, Lyon, France
    Calcif Tissue Int 84:348-54. 2009
    ..Measurements of circulating Dkk-1 with this new ELISA may be useful for the clinical investigation of patients with malignant bone diseases...
  78. ncbi Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide
    Jean Charles Rousseau
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Methods Mol Med 101:25-37. 2004
    ..0001) and 35% (p < 0.001), respectively, suggesting that type IIA collagen synthesis is altered in these arthritic diseases. The measurement of serum PIIANP may be useful for the clinical investigation of patients with joint diseases...
  79. ncbi Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study
    M C Chapuy
    Hopital Edouard Herriot, Lyon, France
    Osteoporos Int 13:257-64. 2002
    ....
  80. ncbi New automated multiplex assay for bone turnover markers in osteoporosis
    Aurélie Claudon
    CCBR SYNARC, Biochemical Markers, Lyon, France
    Clin Chem 54:1554-63. 2008
    ..We evaluated the performance characteristics of a novel, fully automated, protein-array chip system that allows the simultaneous measurement of CTX-I, PINP, OC, and intact parathyroid hormone (PTH) in 20 microL of serum...
  81. ncbi Identification of osteopenic women at high risk of fracture: the OFELY study
    Elisabeth Sornay-Rendu
    INSERM Research Unit 403, E Herriot Hospital, Lyon Cedex 03, France
    J Bone Miner Res 20:1813-9. 2005
    ..In the OFELY study, low BMD, increased markers of bone turnover, and prior fracture could be used to identify, within osteopenic women, those at high risk of fracture...
  82. ncbi Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation
    Ulrich Valcourt
    INSERM Research Unit 403 and Université Lyon 1, Lyon, France
    J Biol Chem 282:5691-703. 2007
    ..We suggest that AGEs may play a role in the alterations of bone remodeling associated with aging and diabetes...
  83. ncbi Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival
    Julia S Johansen
    Department of Rheumatology, Herlev Hospital, Denmark
    Clin Cancer Res 13:3244-9. 2007
    ..In this study, we evaluated the value of these biomarkers in monitoring the patients during hormonal treatment...
  84. ncbi Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy
    Karine Briot
    Faculte de Medecine, Universite Paris Descartes, UPRES EA 4058, Hopital Cochin, Paris, France
    J Rheumatol 35:310-4. 2008
    ..We describe the effects of etanercept on biochemical markers of type II collagen synthesis and degradation in patients with SpA followed for 2 years...
  85. ncbi Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake
    Pierre J Meunier
    Faculty of Medicine RTH, Laennec INSERM Unit 403, Rue G Paradin, 69372 Lyon Cedex 08, France
    Osteoporos Int 16:1203-9. 2005
    ..This could contribute to the repair of calcium deficiency and to the reduction of age-related bone loss in this population...
  86. doi Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
    Allan Lipton
    Department of Hematology Oncology, Milton S Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA
    Cancer 113:193-201. 2008
    ..For patients with bone metastases, high N-telopeptide of type I collagen (NTX) levels correlate with increased risks of skeletal-related events and death. However, the relation between NTX decreases and clinical benefits is unclear...
  87. ncbi Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown
    Changhai Ding
    Menzies Research Institute, University of Tasmania, Hobart, Australia
    Osteoarthritis Cartilage 13:198-205. 2005
    ..To generate hypotheses regarding the associations between knee cartilage defects and knee radiographic osteoarthritis (ROA), cartilage volume, bone size and type II collagen breakdown in adults...
  88. ncbi Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial
    Douglas C Bauer
    Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California 94107, USA
    J Bone Miner Res 21:292-9. 2006
    ..The nonspine fracture efficacy of alendronate was significantly greater among both osteoporotic and nonosteoporotic women with higher baseline levels of the bone formation marker PINP...
  89. ncbi Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial
    Guillaume Chevrel
    Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon France
    J Bone Miner Res 21:300-6. 2006
    ..The mean increases in the lumbar spine BMD were 10.1 +/- 9.8% (p < 0.001) and 0.7 +/- 5.7% in the alendronate and placebo groups, respectively. Oral alendronate increases BMD in adult patients with osteogenesis imperfecta...
  90. ncbi Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial
    Douglas C Bauer
    Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California 94105, USA
    J Bone Miner Res 19:1250-8. 2004
    ..In the alendronate group (n = 3105), greater reductions in one or more biochemical marker were associated with a lower risk of fracture...
  91. ncbi The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women
    Stefan Arrenbrecht
    R W Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
    Maturitas 48:197-207. 2004
    ....
  92. ncbi Correlates of knee pain in younger subjects
    Guangju Zhai
    Menzies Research Institute, University of Tasmania, Hobart, Tasmania, 7001, Australia
    Clin Rheumatol 26:75-80. 2007
    ..MRI and biochemical measures can add to radiographs in defining unexplained knee pain in younger subjects...
  93. ncbi Serum leptin as a determinant of bone resorption in healthy postmenopausal women
    Christian Roux
    Centre d Evaluation des Maladies Osseuses, Departement de Rhumatologie, Hopital Cochin AP HP, Universite Rene Descartes, Paris, France
    Bone 33:847-52. 2003
    ..In conclusion, leptin may play a role as a determinant of bone resorption in healthy, untreated postmenopausal women, but the effect of estradiol or tibolone on bone are not mediated by leptin...
  94. ncbi The DASH diet and sodium reduction improve markers of bone turnover and calcium metabolism in adults
    Pao Hwa Lin
    Department of Medicine, Sarah W Stedman Center for Nutritional Studies, Duke University Medical Center, Durham, NC, USA
    J Nutr 133:3130-6. 2003
    ..A reduced sodium intake reduced calcium excretion in both diet groups and serum OC in the DASH group. The DASH diet and reduced sodium intake may have complementary, beneficial effects on bone health...
  95. ncbi Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis
    Christian Roux
    Groupe de Recherche et d Information sur les Ostéoporoses Task Force for Research and Information on Osteoporosis, Hopital Cochin, 27, rue du Faubourg St Jacques, 75014, Paris, France
    Joint Bone Spine 72:26-31. 2005
    ..Biochemical markers for bone turnover can be monitored after only 3-6 months provided steps are taken to control for intraindividual variability. They are useful when patient compliance is poor or the treatment response inadequate...
  96. ncbi Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA
    Arthritis Rheum 54:3494-507. 2006
    ....
  97. ncbi Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls
    Serge Cremers
    Department of Medicine, Endocrinology, Columbia University, New York, NY, USA
    Drugs 66:2031-58. 2006
    ..Correctly manipulating these may improve clinical development of drugs for the treatment of patients with metabolic bone diseases such as osteoporosis and cancer metastatic to the bone...
  98. ncbi The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
    Dennis M Black
    Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94105, USA
    N Engl J Med 349:1207-15. 2003
    ..We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone...
  99. ncbi Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials
    Walter P Maksymowych
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Rheumatol 34:634-40. 2007
    ..Our objective was to develop validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting radiological endpoints in RA and SpA clinical trials...
  100. ncbi Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women
    Kaisa K Ivaska
    Clinical and Molecular Osteoporosis Research Unit, Department of Orthopaedics, Lund University, Malmo University Hospital, Malmo, Sweden
    J Bone Miner Res 22:1155-64. 2007
    ..Markers were not altered in the immediate postfracture period but were clearly elevated during fracture repair. Recent fracture should thus be taken into account when markers are used in clinical practice...
  101. pmc Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
    Bernard Mazieres
    Department of Rheumatology, Rangueil University Hospital1, avenue Jean Poulhes, 31059 Toulouse Cedex 9, France
    Ann Rheum Dis 66:639-45. 2007
    ..To evaluate the efficacy and tolerability of chondroitin sulphate (chondroitin sulphate) in knee osteoarthritis...